Chetasi Talati, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

ChetasiTalatiMD

Oncology Tampa, FL

Hematologic Oncology

Assistant Member

Overview of Dr. Talati

Dr. Chetasi Talati is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. She received her medical degree from Other and has been in practice 7 years. She is one of 136 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology.

Education & Training

  • University at BuffaloResidency, Internal Medicine, 2012 - 2015
  • OtherClass of 2010

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2015 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
    Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
    Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
    Chetasi Talati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Hospital Affiliations